Share price movements

On May 13, Teva Pharmaceutical (TEVA) closed at $12.23, 14.83% lower than its previous day’s close, 12.89% lower than its 52-week low of $14.04, and 52.89% lower than its 52-week high of $25.96. The company’s market cap is $13.54 billion, and its forward PE, PS (price-to-sales), PB (price-to-book), and PC (price-to-cash) ratios are 4.75, 0.75x, 0.90x, and 6.86x, respectively.

The steep fall in its share price was triggered by a lawsuit filed by 44 US states accusing it of price-fixing in collusion with 19 other drug companies.

What Are Analysts Recommending for TEVA and ENDP in May?

Teva Pharmaceutical’s 14-day RSI (relative strength index) is currently 20.75. The company’s number of outstanding shares is 1.11 billion, while its short float ratio is 1.73%.

On May 13, Endo International (ENDP) closed at $6.51, 19.23% lower than its previous day’s close, 9.97% higher than its 52-week low of $5.92, and 64.81% lower than its 52-week high of $18.50. The company’s market cap is $1.46 billion, and its forward PE, PS, and PC ratios are 2.66x, 0.50x, and 1.49x, respectively. The fall in the company’s share price was triggered by JPMorgan Chase’s changing its rating from a “neutral” to an “underweight.”

Endo International’s 14-day RSI is currently 32.31. The company’s current number of outstanding shares is 224.64 million, while its short float ratio is 9.44%.

Analysts’ recommendations and target prices

The consensus recommendation for both Teva Pharmaceutical and Endo International is a “hold.”

Wall Street analysts expect Teva Pharmaceutical to have a potential upside of 53.80% based on the stock’s closing price on May 13. Analysts have gradually reduced the stock’s 12-month consensus target price from $21.23 in February to $20.50 in March to $19.90 in April and finally to $18.81 in May.

Of the 26 analysts covering Teva Pharmaceutical, two have given it “strong buys,” four have given it “buys,” 18 have given it “holds,” and two have given it “sells.”

Analysts expect a potential upside of 107.37% for Endo International based on the stock’s closing price on May 13. Analysts have gradually reduced the company’s 12-month consensus target price from $15.96 in February to $14.42 in March to $14.17 in April and finally to $13.50 in May.

Of the 15 analysts covering Endo International, two have given it “strong buys,” two have given it “buys,” ten have given it “holds,” and one has given it a “sell.”

Latest articles

After opening on a bearish note on Wednesday, Tesla (TSLA) was trading with 4.8% losses for the day, near $195.25 at 1:16 PM ET.

With voting conducted in seven phases panning six weeks, India’s (EPI) elections have been a grand affair—to say the least. Tomorrow is the day of the results.

Qualcomm (QCOM) stock fell more than 10% in the first half of trading on May 22 after it lost its licensing lawsuit with the US FTC (Federal Trade Commission).

Apple (AAPL) suffered a setback recently when the US Supreme Court allowed an antitrust lawsuit against the company to proceed.

Today doesn’t seem to be a good day for electric vehicle companies. Earlier today, NIO stock hit an all-time low of $4.00.

22 May

Cannabis Stocks Struggle to Find Direction

WRITTEN BY Adam Jones

The cannabis sector has been struggling to find direction on May 22, with cannabis stocks trading on a largely mixed note in the first half.

172.31.16.229